Background: Thenasal and bronchial mucosa present similarities and mostpatients with asthma also have rhinitis, suggesting the concept of ‘one airway one disease’. Although many studies may suggest the relationship between nasal and bronchial responsiveness in patients with allergic rhinitis and asthma, few studies have been published which address this question directly. The aim of this study is to investigate whether the relationship between nonspecific nasal and bronchial responsiveness exists in perennial allergic rhinitic patients with asthma. Methods: Fifty-one perennial allergic rhinitic patients with the definitive or suspected asthma underwent methacholine bronchial provocation tests and nasal histamine challenge tests. A slope of the absolute changes in nasal symptoms score/log concentrations of histamine was calculated by linear regression analysis. A ratio of the final absolute change in nasal symptoms score to the sum of all the doses of histamine given to the subject was also calculated. The degree of bronchial responsiveness to methacholine was categorized as positive bronchial hyperresponsiveness (BHR) if PC20 (provocative concentration of methacholine resulting in 20% fall in FEV1) was <4 mg/ml, borderline BHR if PC20 was ≧4 but ≤16 mg/ml, and negative BHR if PC20 was >16 mg/ml. Another index of bronchial responsiveness (BRindex) was calculated as the log [(% decline in FEV1/log final methacholine concentration as mg/dl) + 10]. Results: The geometric means of the slope (4.47 vs. 2.95, p < 0.05) and the ratio (1.68 vs. 0.54, p < 0.01) were higher in patients with positive BHR (n = 23) than in patients with negative BHR (n = 19), respectively. The geometric means of the slope (3.50) and the ratio (1.13) in patients with borderline BHR (n = 9) were between the two groups, respectively. In all patients, the log-slope (r = 0.48, p < 0.001) and the log-ratio (r = 0.51, p < 0.001) were correlated well with the BRindex, respectively. Even in allergic rhinitic patients with definitive asthma, the log-slope was correlated with the BRindex (r = 0.39, p < 0.05) or log-PC20 (r = –0.36, p < 0.05). Conclusions: The nonspecific nasal responsiveness may be related to the nonspecific bronchial responsiveness in patients with allergic rhinitis and asthma, which may support the viewpoint that allergic rhinitis and asthma represent a continuum of inflammation involving one common airway.

Keywords:
Allergic rhinitis, Asthma, Bronchial responsiveness, Nasal responsiveness
1.
Vignola AM, Bousquet J: Rhinitis and asthma: A continuum of disease? Clin Exp Allergy 2001;31:674–677.
2.
Vignola AM, Chanez P, Godard P, Bousquet J: Relationships between rhinitis and asthma. Allergy 1998;53:833–839.
3.
Simons FE: Allergic rhinobronchitis: The asthma-allergic rhinitis link. J Allergy Clin Immunol 1999;104:534–540.
4.
Wright AL, Holberg CJ, Martinez FD, Halonen M, Morgan W, Taussig LM: Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics 1994;94:895–901.
5.
Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F: Perennnial rhinitis: An independent risk factor for asthma in nonatopic subjects: Results from the European Community Respiratory Health Survey. J Allergy Clin Immunol 1999;104:301–304.
6.
Yawn BP, Yunginger JW, Wollan PC, Reed CE, Silverstein MD, Harris AG: Allergic rhinitis in Rochester, Minnesota residents with asthma: Frequency and impact on health care charges. J Allergy Clin Immunol 1999;103:54–59.
7.
Gaga M, Lambrou P, Papageorgiou N, Koulouris NG, Kosmas E, Fragakis S, Sofios C, Rasidakis A, Jordanoglou J: Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis. Clin Exp Allergy 2000;30:663–669.
8.
Fontanari P, Burnet H, Zattara-Hartmann MC, Jammes Y: Changes in airway resistance induced by nasal inhalation of cold dry, dry, or moist air in normal individuals. J Appl Physiol 1996;81:1739–1743.
9.
Togias AG: Systemic immunologic and inflammatory aspects of allergic rhinitis. J Allergy Clin Immunol 2000;106(suppl 5):247–250.
10.
Watson WT, Becker AB, Simons FE: Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: Effect on lower airway responsiveness. J Allergy Clin Immunol 1993;9:97–101.
11.
Corren J, Adinoff AD, Buchmeier AD, Irvin CG: Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. J Allergy Clin Immunol 1992;90:250–256.
12.
Fokkens WJ, Godthelp T, Holm AF, Blom H, Klein-Jan A: Allergic rhinitis and inflammation: The effect of nasal corticosteroid therapy. Allergy 1997;52(suppl 36):29–32.
13.
Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM: Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720–1745.
14.
Chakir J, Laviolette M, Turcotte H, Boutet M, Boulet LP: Cytokine expression in the lower airways of nonasthmatic subjects with allergic rhinitis: Influence of natural allergen exposure. J Allergy Clin Immunol 2000;106:904–910.
15.
Gerth Van Wijk R, Dieges PH: Comparison of nasal responsiveness to histamine, methacholine and phentolamine in allergic rhinitis patients and controls. Clin Allergy 1987;17:563–570.
16.
Corrado OJ, Gould CA, Kassab JY, Davies RJ: Nasal response to rhinitic and non-rhinitic subjects to histamine and methacholine: A comparative study. Thorax 1986;41:863–868.
17.
Losewicz S, Gomez E, Clague J, Gatland D, Davies RJ: Allergen-induced changes in the nasal mucous membrane in seasonal allergic rhinitis: Effect of nedocromil sodium. J Allergy Clin Immunol 1990;85:125–131.
18.
Baroody FM, Cruz AA, Lichtenstein LM, Kagey-Sobotka A, Proud D, Naclerio RM: Intranasal beclomethasone inhibits antigen-induced nasal hyperresponsiveness to histamine. J Allergy Clin Immunol 1992;90:373–376.
19.
Cockcroft DW, Hargreave FE: Airway hyperresponsiveness. Relevance of random population data to clinical usefulness. Am Rev Respir Dis 1990;142:497–500.
20.
Corren J, Adinoff AD, Irvin CG: Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol 1992;89:611–618.
21.
Skoner DP: Allergic rhinitis: Definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 2001;108 (suppl 1):2–8.
22.
American Thoracic Society: Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease and asthma. Am Rev Respir Dis 1987;136:225–244.
23.
Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O’Byrne PM, Anderson SD, Juniper EF, Malo JL: Airway responsiveness: Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J 1993;6(suppl 16):53–83.
24.
American Thoracic Society: Standardization of spirometry: 1987 update. Am Rev Respir Dis 1987;136:1285–1298.
25.
American Thoracic Society: Guidelines for methacholine and exercise challenge testing – 1999. Am J Respir Crit Care Med 2000;161:309–329.
26.
Burrows B, Sears MR, Flannery EM, Herbison GP, Holdaway MD: Relationship of bronchial responsiveness assessed by methacholine to serum IgE, lung function, symptoms, and diagnoses in 11-year-old New Zealand children. J Allergy Clin Immunol 1992;90:376–385.
27.
Simola M, Malmberg H: Nasal histamine reactivity; relationships to skin-test responses, allergen provocation and symptom severity in patients with long-continuing allergic rhinitis. Acta Otolaryngol 2000;120:67–71.
28.
Corren J: Allergic rhinitis and asthma: How important is the link? J Allergy Clin Immunol 1997;99:S781–S786.
29.
Denburg JA, Inman MD, Sehmi R, Uno M, O’Byrne PM: Hemopoietic mechanisms in allergic airway inflammation. Int Arch Allergy Immunol 1998;117:155–159.
30.
Masuyama K, Till SJ, Jacobson MR, Kamil A, Cameron L, Juliusson S, Lowhagen O, Kay AB, Hamid QA, Durham SR: Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: Effect of topical corticosteroids. J Allergy Clin Immunol 1998;102:610–617.
31.
Braunstahl GJ, Kleinjan A, Overbeek SE, Prins JB, Hoogsteden HC, Fokkens WJ: Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000;161:2051–2057.
32.
Hellings PW, Hessel EM, Van Den Oord JJ, Kasran A, Van Hecke P, Ceuppens JL: Eosinophilic rhinitis accompanies the development of lower airway inflammation and hyper-reactivity in sensitized mice exposed to aerosolized allergen. Clin Exp Allergy 2001;31:782–790.
33.
Greiff L, Andersson M, Svensson C, Linden M, Wollmer P, Brattsand R, Persson CG: Effects of orally inhaled budesonide in seasonal allergic rhinitis. Eur Respir J 1998;11:1268–1273.
34.
McLean JA, Mathews KP, Solomon WR, Brayton PR, Ciarkowski AA: Effect of histamine and methacholine on nasal airway resistance in atopic and nonatopic subjects. Comparison with bronchial challenge and skin test responses. J Allergy Clin Immunol 1977;59:165–170.
35.
Kolbeck KG, Ehnhage A, Juto JE: Nasal and bronchial histamine reactivity in patients with allergic rhinitis out of season. Ann Allergy Asthma Immunol 1999;82:55–60.
36.
Plavec D, Godnic-Cvar J: Lack of correlation between nonspecific nasal and bronchial reactivity in allergic rhinitis subjects. Lung 1999;177:169–177.
37.
Juniper EF, Frith PA, Dunnett C, Cockcroft DW, Hargreave FE: Reproducibility and comparison of responses to inhaled histamine and methacholine. Thorax 1978;33:705–710.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.